No Routine Serologic Testing is Recommended After Shingrix Vaccination
There is no clinically validated or recommended method to assess Shingrix vaccine effectiveness through post-vaccination antibody testing in patients with prior chickenpox. The vaccine's effectiveness is measured by clinical outcomes (prevention of shingles), not by laboratory markers.
Why Post-Vaccination Testing is Not Useful
Guidelines Explicitly Recommend Against Screening
Current international guidelines, including those from the US CDC, Canadian, and German authorities, recommend against serologic testing before OR after herpes zoster vaccination in immunocompetent adults aged ≥50 years 1. This recommendation is based on:
- High baseline VZV seropositivity (88-91% in most populations)
- No safety concerns with vaccinating already seropositive individuals
- Lack of established serologic correlates of protection for Shingrix
No Validated Correlate of Protection Exists
Unlike some vaccines where specific antibody levels predict protection, Shingrix effectiveness cannot be reliably assessed through standard antibody testing 2. The vaccine works through:
- Cell-mediated immunity (T-cell responses)
- Antibody-dependent cellular phagocytosis (ADCP)
- Antibody-dependent cellular cytotoxicity (ADCC)
- Anti-glycoprotein E (anti-gE) antibodies
While anti-gE antibody levels can be measured by ELISA in research settings 2, 3, these measurements are not standardized for clinical use and do not reliably predict individual protection.
How Vaccine Effectiveness is Actually Determined
Clinical Outcomes are the Gold Standard
Shingrix effectiveness is demonstrated by:
- Real-world prevention of shingles episodes: 76% effectiveness with 2 doses, 64% with 1 dose 4
- Sustained protection over time: 73-79% effectiveness maintained through 4 years after 2 doses 4
- Prevention of complications: 89% effectiveness against herpes zoster ophthalmicus 5, substantial reduction in postherpetic neuralgia 2, 6
The Critical Importance of Two Doses
One dose provides inadequate and rapidly waning protection 4:
- 1-dose effectiveness: 70% at year 1, declining to 45-52% by years 2-3
- 2-dose effectiveness: 79% at year 1, maintaining 73-75% through year 4
This underscores why completion of the 2-dose series is essential, regardless of any theoretical antibody response.
Practical Clinical Approach
For Your VZV-Seropositive Patient
- Ensure completion of the 2-dose series (0 and 2 months) 2
- Do not order post-vaccination antibody testing - it provides no actionable information
- Assess effectiveness clinically: The patient is protected if they don't develop shingles over subsequent years
Special Considerations for Immunocompromised Patients
For immunocompromised adults, providers may consider pre-vaccination serology testing to guide decision-making between varicella vaccine (if seronegative) versus Shingrix (if seropositive) 1. However, post-vaccination testing remains non-informative even in this population.
Common Pitfalls to Avoid
- Do not confuse VZV IgG testing with vaccine response assessment: Prior chickenpox immunity (VZV IgG+) is not the same as vaccine-induced protection against shingles
- Do not delay or skip the second dose: Single-dose protection is inadequate and wanes rapidly
- Do not order "zoster titers": No such validated test exists for clinical decision-making
- Do not assume breakthrough shingles means vaccine failure: Even with 76-89% effectiveness, some vaccinated individuals will still develop shingles, though typically with reduced severity 4, 6
The vaccine's success is measured by population-level reduction in shingles incidence and individual absence of disease, not by laboratory values.